Posted by Michael Wonder on 01 Apr 2019
PHARMAC called out over failure to fund breast cancer drug Ibrance
2 April 2019 - PHARMAC is being called out for trailing behind Australia when it comes to funding breast cancer drug, Ibrance.
It allows patients to work while taking it and avoid chemotherapy.
Breast Cancer Foundation chief executive Evangelia Henderson told Newshub PHARMAC must take note.
"Not only have [Australia] got Ibrance funded but they actually have other drugs like it funded."
Editor's note - Ibrance will be listed on the Australian Pharmaceutical Benefits Scheme on 1 May 2019.
